DaVita (NYSE:DVA – Free Report) had its price objective raised by TD Cowen from $144.00 to $201.00 in a research report sent to investors on Monday morning, Marketbeat reports. They currently have a hold rating on the stock.
DVA has been the topic of several other research reports. Truist Financial lifted their target price on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. Barclays boosted their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. UBS Group boosted their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average price target of $199.17.
DaVita Stock Down 1.2%
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts forecast that DaVita will post 15.07 EPS for the current year.
Insider Activity
In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Root Financial Partners LLC raised its holdings in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Caitlin John LLC acquired a new position in DaVita in the 4th quarter valued at $34,000. Sankala Group LLC acquired a new position in DaVita in the 4th quarter valued at $39,000. Finally, Canada Pension Plan Investment Board acquired a new position in DaVita during the second quarter worth approximately $43,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Key DaVita News
Here are the key news stories impacting DaVita this week:
- Positive Sentiment: DaVita’s latest quarter beat expectations on both earnings and revenue, with EPS of $2.87 versus $2.33 expected and revenue of $3.42 billion versus $3.36 billion projected. Revenue also rose 6% year over year, supporting the case for improved operating performance. Article Title
- Positive Sentiment: Analysts turned more constructive after earnings: Deutsche Bank upgraded the stock to Buy and raised its target to $220, UBS lifted its target to $235, TD Cowen increased its target to $201, and Barclays raised its target to $194. The average target now sits near $199, suggesting valuation support near current levels. Article Title
- Positive Sentiment: Zacks highlighted DaVita as a strong momentum stock and also included it on its list of Strong Buy growth names, reinforcing the market’s bullish short-term sentiment. Article Title
- Neutral Sentiment: The company presented at the Bank of America Global Healthcare Conference, where management likely reinforced the earnings and operating outlook, but no major new announcement was highlighted in the transcript headline. Article Title
- Negative Sentiment: CFO Joel Ackerman sold 51,471 shares, worth about $9.9 million. While insider selling does not automatically signal trouble, it can create a small overhang for investors near recent highs. Article Title
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Articles
- Five stocks we like better than DaVita
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
